Low-dose<i>i</i>nterleukin 2 for the reduction of<i>v</i>ascular inflammati<i>o</i>n in acute corona<i>ry</i>syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial
BMJ open